| Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes B Chapuy, C Stewart, AJ Dunford, J Kim, A Kamburov, RA Redd, ... Nature medicine 24 (5), 679-690, 2018 | 1550 | 2018 |
| PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome MGM Roemer, RH Advani, AH Ligon, Y Natkunam, RA Redd, H Homer, ... Journal of Clinical Oncology 34 (23), 2690, 2016 | 783 | 2016 |
| Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation RC Lindsley, W Saber, BG Mar, R Redd, T Wang, MD Haagenson, ... New England Journal of Medicine 376 (6), 536-547, 2017 | 703 | 2017 |
| Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma MGM Roemer, RA Redd, FZ Cader, CJ Pak, S Abdelrahman, J Ouyang, ... Journal of Clinical Oncology 36 (10), 942, 2018 | 310 | 2018 |
| Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma Z Hu, DE Leet, RL Allesøe, G Oliveira, S Li, AM Luoma, J Liu, J Forman, ... Nature medicine 27 (3), 515-525, 2021 | 304 | 2021 |
| Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma CD Carey, D Gusenleitner, M Lipschitz, MGM Roemer, EC Stack, E Gjini, ... Blood, The Journal of the American Society of Hematology 130 (22), 2420-2430, 2017 | 304 | 2017 |
| Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity CA Jacobson, BD Hunter, R Redd, SJ Rodig, PH Chen, K Wright, ... Journal of Clinical Oncology 38 (27), 3095, 2020 | 260 | 2020 |
| Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma P Armand, S Rodig, V Melnichenko, C Thieblemont, K Bouabdallah, ... Journal of Clinical Oncology 37 (34), 3291, 2019 | 251 | 2019 |
| Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study R Ramchandren, E Domingo-Domènech, A Rueda, M Trněný, ... Journal of Clinical Oncology 37 (23), 1997, 2019 | 208 | 2019 |
| Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status MGM Roemer, RH Advani, RA Redd, GS Pinkus, Y Natkunam, AH Ligon, ... Cancer immunology research 4 (11), 910-916, 2016 | 183 | 2016 |
| PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation P Armand, YB Chen, RA Redd, RM Joyce, J Bsat, E Jeter, RW Merryman, ... Blood, The Journal of the American Society of Hematology 134 (1), 22-29, 2019 | 157 | 2019 |
| Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression M Bustoros, R Sklavenitis-Pistofidis, J Park, R Redd, B Zhitomirsky, ... Journal of Clinical Oncology 38 (21), 2380, 2020 | 138 | 2020 |
| Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment FZ Cader, RCJ Schackmann, X Hu, K Wienand, R Redd, B Chapuy, ... Blood, The Journal of the American Society of Hematology 132 (8), 825-836, 2018 | 136 | 2018 |
| The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? AM Vanderbeek, R Rahman, G Fell, S Ventz, T Chen, R Redd, ... Neuro-oncology 20 (8), 1034-1043, 2018 | 122 | 2018 |
| Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion K Wienand, B Chapuy, C Stewart, AJ Dunford, D Wu, J Kim, A Kamburov, ... Blood advances 3 (23), 4065-4080, 2019 | 116 | 2019 |
| Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant TH Mouhieddine, AS Sperling, R Redd, J Park, M Leventhal, CJ Gibson, ... Nature communications 11 (1), 2996, 2020 | 115 | 2020 |
| A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma FZ Cader, X Hu, WL Goh, K Wienand, J Ouyang, E Mandato, R Redd, ... Nature medicine 26 (9), 1468-1479, 2020 | 105 | 2020 |
| Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity CA Jacobson, B Hunter, P Armand, Y Kamihara, J Ritz, SJ Rodig, ... Blood 132, 92, 2018 | 104 | 2018 |
| Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade B Chapuy, C Stewart, AJ Dunford, J Kim, K Wienand, A Kamburov, ... Blood, The Journal of the American Society of Hematology 134 (26), 2369-2382, 2019 | 89 | 2019 |
| A phase Ib/II trial of the first-in-class anti-CXCR4 antibody ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma IM Ghobrial, CJ Liu, RA Redd, RP Perez, R Baz, O Zavidij, ... Clinical Cancer Research 26 (2), 344-353, 2020 | 82 | 2020 |
